Advanced Search

Study Preview



Study Title and Description

The effect of caffeine on retinal vessel diameter in young healthy subjects.



Key Questions Addressed
1 For [population], is caffeine intake above [exposure dose], compared to intakes [exposure dose] or less, associated with adverse effects on cardiovascular outcomes?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title The effect of caffeine on retinal vessel diameter in young healthy subjects.
Author N Terai,E Spoerl,LE Pillunat,R Stodtmeister,
Country
Year 2012
Numbers

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Cardiovascular Design
Design Details
Question... Follow Up Answer Follow-up Answer
What outcome is being evaluated in this paper? Cardiovascular
  • Comments Comments (
    0
    ) |
What is the objective of the study (as reported by the authors)? To investigate the effect of caffeine on retinal vessel diameter before and during flicker light stimulation in young healthy subjects.
  • Comments Comments (
    0
    ) |
Provide a general description of the methods as reported by the authors. Information should be extracted based on relevance to the SR (i.e., caffeine related methods) Before retinal vessel analysis, all subjects had to pass an ophthalmic examination including slit-lamp biomicroscopy, indirect funduscopy, measurement of intraocular pressure (IOP) with Goldmann applanation tonometry (GAT) and measurement of pulse rate and systemic blood pressure. All measurements were undertaken in the right eye after using tropicamid 0.5% (Mydrum, Ankerpharm) for pupil dilatation.
  • Comments Comments (
    0
    ) |
How many outcome-specific endpoints are evaluated? 4
  • Comments Comments (
    0
    ) |
What is the (or one of the) endpoint(s) evaluated? (Each endpoint listed separately) Blood pressure (systolic and diastolic, mean arterial pressure)
  • Comments Comments (
    0
    ) |
List additional health endpoints (separately). 2 Ocular perfusion pressure
  • Comments Comments (
    0
    ) |
List additional health endpoints (separately).3 Intraocular pressure
  • Comments Comments (
    0
    ) |
List additional health endpoints (separately).4 Pulse
  • Comments Comments (
    0
    ) |
List additional health endpoints (separately).5
  • Comments Comments (
    0
    ) |
List additional health endpoints (separately).6
  • Comments Comments (
    0
    ) |
Clinical, physiological, other Physiological
  • Comments Comments (
    0
    ) |
What is the study design? Controlled Trial
  • Comments Comments (
    0
    ) |
Randomized or Non-Randomized? NCT
  • Comments Comments (
    0
    ) |
What were the diagnostics or methods used to measure the outcome? Objective
  • Comments Comments (
    0
    ) |
Optional: Name of Method or short description Before retinal vessel analysis, all subjects had to pass an ophthalmic examination including slit-lamp biomicroscopy, indirect funduscopy, measurement of intraocular pressure (IOP) with Goldmann applanation tonometry (GAT) and measurement of pulse rate and systemic blood pressure. All measurements were undertaken in the right eye after using tropicamid 0.5% (Mydrum, Ankerpharm) for pupil dilatation.
  • Comments Comments (
    0
    ) |
Caffeine (general) Caffeine (general)
  • Comments Comments (
    0
    ) |
Coffee, Chocolate, energy drink, gum, medicine/supplement, soda, tea, other?
  • Comments Comments (
    0
    ) |
Measured or self reported? Measured
  • Comments Comments (
    0
    ) |
Children, adolescents, adults, or pregnant included? Adults
  • Comments Comments (
    0
    ) |
What was the reference, comparison, or control group(s)? (e.g. high vs low consumption, number of cups, etc.) Subjects were assessed prior to and after ingestion of caffeine.
  • Comments Comments (
    0
    ) |
What were the listed confounders or modifying factors as stated by the authors? (e.g. multi-variable components of models.  Copy from methods) Seventeen young, healthy subjects with no history of diabetes, hypertension or any other systemic diseases were included in this study. Exclusion criteria were as follows: glaucoma, age-related macula degeneration, other ocular diseases, previous intraocular surgery, ocular injuries and lens opacities. Participants with migraine, epilepsy, uncontrolled arterial hypertension, prior steroid therapy < 4 weeks, pregnant and breastfeeding women were also excluded. Changes in retinal vessel diameters were expressed as the absolute diameter changes. Baseline values were calculated as an average of the last 30 seconds before start of the flicker stimulation. Retinal vessel diameters during flicker light stimulation were calculated from the 10–20 seconds of the flicker period. The relationship between the vessel diameter and the mean arterial pressure (MAP) was calculated with the Pearson correlation coefficient and the regression lines. p = 0.05 was considered as the level of significance. Data are presented as the arithmetic mean ± SD. Mean arterial pressure was calculated by the formula: MAP = BPdiast + 1 ⁄ 3(BPsyst – BPdiast), (BPsyst, systolic blood pressure; BPdiastol, diastolic blood pressure). Ocular perfusion pressure (OPP) was calculated by the formula: OPP = 2 ⁄ 3 MAP – IOP.
  • Comments Comments (
    0
    ) |
What conflicts of interest were reported? Not discussed.
  • Comments Comments (
    0
    ) |
Refid 22863322
  • Comments Comments (
    0
    ) |
What were the sources of funding? Not discussed.
  • Comments Comments (
    0
    ) |




Results & Comparisons

No Results found.